In contrast, FH patients may not have been assessed for progression at regular intervals, and, as detailed in Appendix S1, some IMWG criteria for progression, such as development of plasmacytoma, are not included in FH's disease progression algorithm, which considers only laboratory M‐protein and free light chain measurements. The gene discussed is MYOM2; the disease is familial hyperaldosteronism.